与此同时,美国癌症学会估计2024年美国将有大约66440人将被诊断为...查看全文
美股滚雪球2023-09-12 10:16
sell on news,$BioLineRx(BLRX)$ 宣布FDA批准其用于多发性骨髓瘤患者的主要资产Aphexda (motixafortide),这标志着该公司首次获得监管批准,股价不涨反跌。
$百济神州-U(SH688235)$ $君实生物-U(SH688180)$查看全文
产业链观察2023-09-11 20:22
#药闻简讯# $BioLineRx(BLRX)$ 宣布FDA批准APHEXDA与Filgrastim(G-CSF)联用,用于动员多发性骨髓瘤患者的造血干细胞进行采集和随后的自体移植查看全文
美股律师郝俊波2023-01-06 10:39
$BioLineRx(BLRX)$ 【BioLineRx(BLRX)最新证券集体诉讼】
BioLineRx Ltd(NASDAQ: BLRX)因证券欺诈案已经被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司及部分高管在本案诉讼期间进行虚假陈述,违反证券法令投资者受损。投资者向法院申请判令被告赔偿因其违法行为导致股价下跌给投资...查看全文
BioLineRx(BLRX)2023-01-04 20:12
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-000033 Act: 34 Size: 39 KB 网页链接查看全文
BioLineRx(BLRX)04-17 19:15
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001347 Act: 34 Size: 612 KB 网页链接查看全文
BioLineRx(BLRX)04-10 19:35
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001285 Act: 34 Size: 595 KB 网页链接查看全文
BioLineRx(BLRX)04-01 22:45
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001174 Act: 34 Size: 1 MB 网页链接查看全文
BioLineRx(BLRX)04-01 22:35
$BioLineRx(BLRX)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-24-001173 Act: 33 Size: 733 KB 网页链接查看全文
BioLineRx(BLRX)03-27 05:05
$BioLineRx(BLRX)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-24-001095 Act: 34 Size: 14 MB 网页链接查看全文
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001347 Act: 34 Size: 612 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001285 Act: 34 Size: 595 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001174 Act: 34 Size: 1 MB 网页链接
$BioLineRx(BLRX)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001178913-24-001173 Act: 33 Size: 733 KB 网页链接
$BioLineRx(BLRX)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-24-001095 Act: 34 Size: 14 MB 网页链接
$BioLineRx(BLRX)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-24-001075 Act: 34 Size: 13 MB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001072 Act: 34 Size: 445 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000792 Act: 34 Size: 163 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000739 Act: 34 Size: 168 KB 网页链接
$BioLineRx(BLRX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000626 Act: 34 Size: 195 KB 网页链接